Abstract
Duodenal dysbiosis represents a significant infection risk for patients suffering from severe acute pancreatitis (SAP). While acid-suppressing drugs (ACDs) like esomeprazole (Eso) are frequently administered in Asian clinical settings to "rest" the pancreas, their impact on the duodenal microbiome during the acute phase of the disease has remained unclear. This randomized controlled trial evaluated 66 SAP patients to determine how esomeprazole affects duodenal microbial composition and infection rates during the first week of treatment. The study found that acid suppression significantly increased the occurrence of duodenal bacterial overgrowth (DBO) and Candida oesophagitis (CE), suggesting that the routine use of PPIs in SAP may carry substantial microbial risks.
Introduction
Severe acute pancreatitis (SAP) is a life-threatening inflammatory condition. A common therapeutic strategy, particularly in many Asian countries, is to "put the pancreas at rest" by inhibiting gastric acid secretion using proton pump inhibitors (PPIs). This approach is based on the physiological principle that reducing gastric acidity minimizes secretin-mediated pancreatic stimulation.
However, gastric acid serves as a primary biological barrier against ingested pathogens. Previous studies have linked long-term PPI use to small intestinal bacterial overgrowth (SIBO). This study sought to investigate whether the intensive, short-term use of PPIs during the critical first week of SAP disrupts the duodenal microbiota and increases the risk of secondary infections—a leading cause of mortality in SAP patients.
Methods
The researchers conducted a parallel randomized controlled trial involving 66 patients diagnosed with SAP. Participants were randomized in a 1:1 ratio into two groups: the esomeprazole group (Eso), receiving 40 mg/day, and the control group (Eso-N), which received no PPI.
Key methodological steps included:
- Sampling: On the seventh day of treatment, duodenal aspirates and mucosal brushes were collected via endoscopy.
- Microbial Analysis: A dual-track approach was used. Traditional aerobic and anaerobic cultures quantified bacterial load, while 16S rRNA Illumina sequencing (V4-V5 regions) profiled the microbial community structure.
- Bioinformatics: Sequences were clustered into Operational Taxonomic Units (OTUs) at 97% similarity using QIIME. Linear discriminant analysis Effect Size (LEfSe) was employed to identify significantly enriched taxa.
- Controls: 20 healthy volunteers provided a baseline for normal duodenal microbiota.
Results
The study revealed that acid suppression led to rapid and profound changes in the duodenal environment.
Duodenal Bacterial Overgrowth (DBO)
The most prominent finding was the significant increase in DBO within the Eso group. As shown in the figure below, the occurrence of DBO in duodenal aspirates (panel a) was approximately 85% in the Eso group, compared to 42% in the Eso-N group (p < 0.001). Similar trends were observed in mucosal brush samples (panel b), though at slightly lower overall percentages.
Microbial Composition and pH
Intragastric pH was significantly higher in the Eso group (5.15) compared to the Eso-N group (2.70). This loss of acidity facilitated a shift in the duodenal microbiota. The Eso group showed an enrichment of taxa typically found in the oral cavity, such as Veillonella and Streptococcus, as well as the class Negativicutes and order Selenomonadales. This suggests that lowering gastric acidity allows oral microbes to survive transit and colonize the duodenum.
Secondary Infections
While clinical severity scores (APACHE II and Marshall scores) did not differ significantly between groups in the first week, there was a striking difference in fungal infections. Candida oesophagitis (CE) occurred in 24.2% of the Eso group compared to only 3.0% in the Eso-N group (p = 0.013), representing an 8-fold increase.
Discussion and Conclusion
This trial demonstrates that PPI-induced duodenal dysbiosis occurs much faster than previously thought, manifesting within just seven days in SAP patients. The "oral-to-gut" microbial pipeline enabled by acid suppression leads to a homogenized, potentially pathogenic duodenal environment.
The 8-fold spike in Candida infections is a critical "aha" moment, highlighting the gastric acid barrier's role in controlling opportunistic fungal growth. While the dysbiosis did not immediately translate to worse clinical scores in the first week, it may serve as a "silent" risk factor for late-stage complications like infected pancreatic necrosis, which typically develops 4–8 weeks after onset.
In conclusion, acid suppression significantly increases DBO, duodenal dysbiosis, and fungal infection risk during the early phase of SAP. Clinicians should consider a more restrictive use of acid-suppressing medications to mitigate these microbial risks and potentially reduce the incidence of late-stage pancreatic infections. Future multi-center trials are needed to confirm if avoiding routine PPI use improves long-term outcomes in SAP.
Summary updated